The association between biomarkers and neuropsychiatric symptoms across the Alzheimer's disease spectrum

Banning, L.C.P.; Ramakers, I.H.G.B.; Kohler, S.; Bron, E.E.; Verhey, F.R.J.; Deyn, P.P. de; Claassen, J.A.H.R.; Koek, H.L.; Middelkoop, H.A.M.; Flier, W.M. van der; Lugt, A. van der; Aalten, P.; Alzheimers Dis Neuroimaging Initia; Parelsnoer Inst Neurodegenerative

doi:doi:10.1016/j.jagp.2020.01.012

Persistent URL of this record https://hdl.handle.net/1887/3249499

View statistics

In Collections

This item can be found in the following collections:

Medicine / Leiden University Medical Centre (LUMC)

Banning, L.C.P.; Ramakers, I.H.G.B.; Kohler, S.; Bron, E.E.; Verhey, F.R.J.; Deyn, P.P. de; ... ; Parelsnoer Inst Neurodegenerative (2020)

The association between biomarkers and neuropsychiatric symptoms across the Alzheimer's disease spectrum

Article / Letter to editor

Objectiv(e): To investigate the relationship between Alzheimer's disease biomarkers and neuropsychiatric symptoms. Methods: Data from two large cohort studies, the Dutch Parelsnoer Institute - Neurodegenerative Diseases and the Alzheimer's Disease Neuroimaging Initiative was used, including subjects with subjective cognitive decline (N= 650), mild cognitive impairment (N = 887), and Alzheimer's disease dementia (N = 626). Cerebrospinal fluid (CSF) levels of A beta(42), t-tau, p-tau, and hippocampal volume were associated with neuropsychiatric symptoms (measured with the Neuropsychiatric Inventory) using multiple logistic regression analyses. The effect of the Mini-Mental State Examination (as proxy for cognitive functioning) on these relationships was assessed with mediation analyses. Results: Alzheimer's disease biomarkers were not associated with depression, agitation, irritability, and sleep disturbances. Lower levels of CSF A beta(42), higher levels of t- and p-tau were...Show moreObjectiv(e): To investigate the relationship between Alzheimer's disease biomarkers and neuropsychiatric symptoms. Methods: Data from two large cohort studies, the Dutch Parelsnoer Institute - Neurodegenerative Diseases and the Alzheimer's Disease Neuroimaging Initiative was used, including subjects with subjective cognitive decline (N= 650), mild cognitive impairment (N = 887), and Alzheimer's disease dementia (N = 626). Cerebrospinal fluid (CSF) levels of A beta(42), t-tau, p-tau, and hippocampal volume were associated with neuropsychiatric symptoms (measured with the Neuropsychiatric Inventory) using multiple logistic regression analyses. The effect of the Mini-Mental State Examination (as proxy for cognitive functioning) on these relationships was assessed with mediation analyses. Results: Alzheimer's disease biomarkers were not associated with depression, agitation, irritability, and sleep disturbances. Lower levels of CSF A beta(42), higher levels of t- and p-tau were associated with presence of anxiety. Lower levels of CSF A beta(42) and smaller hippocampal volumes were associated with presence of apathy. All associations were mediated by cognitive functioning. Conclusion: The association between Alzheimer's disease pathology and anxiety and apathy is partly due to impairment in cognitive functioning.Show less

Neuropsychiatric symptoms

biomarkers

neurocognitive disorders

mild cognitive impairment

Alzheimer's disease dementia